Dimethyl Sulfoxide
Apexbio Technology LLC CP-724714 537705-08-1 10mM (in 1mL DMSO)
CP-724714 (CAS 537705-08-1) is a small molecule inhibitor selectively targeting erbB2 (Her2) and EGFR kinases with notable potency against erbB2 kinase (IC50 10 3 nM) and considerably lower activity toward EGFR kinase (IC50 6 400 2 100 nM) In cellular assays CP-724714 induces G1 cell-cycle arrest and decreases erbB2 phosphorylation in Her2-overexpressing BT-474 breast cancer cells In animal xenograft models (BT-474 MDA-MB-453) it reduces erbB2 receptor phosphorylation and downstream signaling resulting in tumor growth inhibition and apoptosis induction CP-724714 advanced into phase I clinical trials for Her2-driven breast cancer research
Medchemexpress LLC Dbet6 10Mm 1Md Dmso Reconstit | HY-112588-10MM-DMSO-RECON
Dbet6 10Mm 1Md Dmso Reconstit
Medchemexpress LLC Azd4320 10Mm 1Ml Dmso Reconst | HY112416-10MM-1ML RECONST
Azd4320 10Mm 1Ml Dmso Reconst
Apexbio Technology LLC PCI-32765 (Ibrutinib) 936563-96-1 10mM (in 1mL DMSO)
PCI-32765 (Ibrutinib) is a small-molecule inhibitor targeting Bruton s tyrosine kinase (BTK) a cytoplasmic kinase integral to B-cell receptor (BCR) signaling By covalently binding to BTK active sites PCI-32765 disrupts downstream signaling cascades essential for B-cell maturation and activation Dysfunction or inhibition of BTK correlates with impaired B-cell development and reduction in autoantibody production PCI-32765 is commonly utilized in biomedical research to explore BTK-dependent signaling pathways elucidate molecular mechanisms underlying B-cell mediated disorders and examine therapeutic potential in B-cell malignancies and autoimmune models
AdipoGen DAF-4T Solution 5 mM in DMSO
Chemical. CAS 212558-80-0. Formula C20H7Cl2N3O5. MW 440.19. Fluorescent reference compound for DAF-4 DA CDX-D0216. Spectral data lambdaEx=505nm lambdaEm=530nm.
Apexbio Technology LLC Nexturastat A 1403783-31-2 10mM (in 1mL DMSO)
Nexturastat A (CAS 1403783-31-2) is a selective small-molecule inhibitor of histone deacetylase 6 (HDAC6) It displays potent inhibitory activity against HDAC6 with an IC50 of 5 2 nM While predominantly targeting HDAC6 Nexturastat A also exhibits moderate inhibitory effects on other HDAC isoforms (HDAC1-5 and 7-11) at low micromolar concentrations In cell-based studies including mouse B16 melanoma cell lines Nexturastat A has shown antiproliferative properties and induction of apoptosis Due to its selective HDAC6 inhibition Nexturastat A is utilized in cancer research focusing on epigenetic regulation and therapeutic development
Apexbio Technology LLC Tasquinimod 254964-60-8 10mM (in 1mL DMSO)
Tasquinimod (CAS 254964-60-8) is an orally bioavailable quinoline-3-carboxamide compound with antiangiogenic and antitumor properties It modulates angiogenesis primarily through dual inhibition of S100A9/TLR4 signaling in myeloid-derived suppressor cells (MDSCs) and downregulation of HIF-1 and VEGF expression in tumor and endothelial cells It also enhances thrombospondin-1 (TSP-1) expression further suppressing neovascularization Preclinical studies in human prostate cancer xenograft models indicate significant antineoplastic activity particularly in combination with docetaxel radiation therapy or androgen-depletion strategies suggesting its therapeutic potential for castration-resistant prostate cancer (CRPC)
Apexbio Technology LLC BIX 02189 1094614-85-3 10mM (in 1mL DMSO)
BIX 02189 is a selective kinase inhibitor targeting MEK5 a mitogen-activated protein kinase kinase It belongs to the chemical class of dihydroindolone-based kinase inhibitors Mechanistically BIX 02189 binds and inhibits the catalytic activity of MEK5 leading subsequently to suppression of ERK5 phosphorylation without affecting closely related kinases such as MEK1 MEK2 ERK2 or JNK2 In cellular studies using cultured HeLa and HEK293 cells BIX 02189 inhibits transcriptional activity mediated by downstream substrate MEF2C as well as ERK5 phosphorylation Additionally BIX 02189 has demonstrated inhibition of lymphatic endothelial cell sprouting in three-dimensional lymphangiogenesis assays indicating its applicability in angiogenesis and signal transduction research
Apexbio Technology LLC UMI-77(Synonyms: UMI 77, UMI77, UMI-77 Mcl-1 inhibitor, Mcl-1 inhibitor UMI-77, 518303-20-3), 10mM (in 1mL DMSO), CAS: 518303-20-3.
UMI-77 (CAS 518303-20-3) is a small-molecule inhibitor targeting the anti-apoptotic protein Myeloid cell leukemia-1 (Mcl-1) a member of the Bcl-2 protein family implicated in apoptotic regulation and cell survival signaling Biochemical assays demonstrate that UMI-77 binds selectively to the BH3-binding groove of Mcl-1 protein competing effectively against pro-apoptotic BH3 peptides (Ki 0 49 M) Additionally UMI-77 disrupts the interaction of Mcl-1 with pro-apoptotic factors such as Bax (IC50 1 43 M) promoting apoptosis in cancer cells Preclinical studies on pancreatic cancer cell lines and BxPC-3 xenograft mouse models show that UMI-77 suppresses tumor growth and induces apoptotic cell death highlighting its value as a research tool for studying apoptosis-related oncogenic pathways
Apexbio Technology LLC ML347 1062368-49-3 10mM (in 1mL DMSO)
ML347 (CAS 1062368-49-3) is a potent and selective inhibitor of bone morphogenetic protein (BMP) type I receptors specifically targeting ALK2 Mechanistically ML347 selectively inhibits ALK2 kinase activity with an IC50 of 32 nM while also inhibiting ALK1 with a comparable IC50 of 46 nM Notably ML347 displays approximately 300-fold selectivity for ALK2 over ALK3 and lacks inhibitory activity against closely related kinases such as ALK6 and KDR In the BMP4-induced C2C12BRA cell-based assay ML347 exhibits inhibitory activity with an IC50 of 152 nM As a selective ALK2 inhibitor ML347 serves as a valuable probe in BMP pathway research
Apexbio Technology LLC Influenza Hemagglutinin (HA) Peptide 92000-76-5 10mM (in 1mL DMSO)
Influenza hemagglutinin (HA) peptide (sequence YPYDVPDYA) is commonly utilized in biomedical studies as an epitope tag for protein detection and isolation Derived from the influenza virus hemagglutinin protein HA mediates viral entry into host cells through initial receptor binding (via HA1 subunit) and subsequent membrane fusion (via HA2 subunit) Under acidic intracellular conditions HA undergoes conformational changes enabling membrane destabilization and viral fusion Synthetic HA-derived peptides can mimic this fusogenic mechanism enhancing gene transfer efficiency in vitro through promoting cellular uptake of transfection complexes in various cultured cell lines including K562 HeLa and BNL CL 2 hepatocyte cells Typically employed within transferrin-polylysine-DNA based delivery systems these HA peptides facilitate membrane disruption increasing complex internalization reported IC50 values vary depending on specific cellular systems and experimental conditions
Apexbio Technology LLC CEP-18770 847499-27-8 10mM (in 1mL DMSO)
CEP-18770 (CAS 847499-27-8) is a reversible boronic acid-based inhibitor of proteasome chymotrypsin-like activity It specifically targets the proteasome s P2 threonine protease subunit reducing NF- B signaling and the expression of downstream effectors With a reported IC50 of 3 8 nM CEP-18770 induces apoptosis in multiple myeloma cell lines and inhibits osteoclastogenesis and angiogenesis via suppression of RANKL signaling Research supports its potential use in oncology particularly for multiple myeloma showing selective cytotoxicity sparing normal epithelial and bone marrow-derived cells